Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
1 other identifier
interventional
2,781
26 countries
359
Brief Summary
The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jun 2014
Typical duration for phase_3
359 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2014
CompletedFirst Posted
Study publicly available on registry
June 25, 2014
CompletedStudy Start
First participant enrolled
June 26, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 4, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
October 4, 2018
CompletedResults Posted
Study results publicly available
December 16, 2019
CompletedDecember 16, 2019
November 1, 2019
4.3 years
June 24, 2014
October 4, 2019
November 27, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.
Baseline (Day 1, Week 0) and Week 28 to Week 52.
Secondary Outcomes (10)
Percentage of Participants With Hb Response During the First 24 Weeks of Treatment
Baseline (Day 1, Week 0) up to Week 24.
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)
Baseline (Day 1, Week 0) and Week 28 to Week 52.
Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52
Week 28 up to Week 52.
Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52
Week 28 up to Week 52.
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24
Baseline (Day 1, Week 0) and Week 24
- +5 more secondary outcomes
Study Arms (2)
Roxadustat
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
Eligibility Criteria
You may qualify if:
- Provision of informed consent prior to any study specific procedures.
- Age ≥18 years at screening visit 1
- eGFR \<60 mL/min/1.73 m2, (calculated by central lab) corresponding to stage 3, 4 or 5CKD according to the Kidney Disease Outcomes Quality Initiative (KDOQI), not receiving dialysis
- Mean of 2 most recent central laboratory Hb values during the screening period, obtained at least 7 days apart, must be \<10.0 g/dL
- Ferritin ≥50 ng/mL at randomization (obtained from screening visit)
- TSAT ≥15 % at randomization (obtained from screening visit)
- Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from screening visit)
- Serum vitamin B12 level ≥LLN at randomization (obtained from screening visit)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) and total bilirubin (Tbili) ≤1.5 x ULN at randomization (obtained from screening visit)
- Body weight 45 to 160 kg
You may not qualify if:
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- Previous randomization in the present study
- Any erythropoietin analogue treatment within 6 weeks of randomization
- New York Heart Association Class III or IV congestive heart failure at enrollment
- Myocardial infarction (MI), acute coronary syndrome, stroke, seizure or a thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization
- History of chronic liver disease (e.g., chronic infectious hepatitis, chronic auto- immune liver disease, cirrhosis or fibrosis of the liver)
- Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a history of pure red cell aplasia or other known causes for anemia other than CKD
- Known and untreated retinal vein occlusion or known and untreated proliferative diabetic retinopathy (risk for retinal vein thrombosis)
- Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV) of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan or MRI) conducted at screening or within 12 weeks prior to randomization
- Systolic BP ≥160 mmHg or diastolic BP ≥95 mmHg (confirmed by repeated measurement), within 2 weeks prior to randomization. Patients may be rescreened once BP controlled
- History of prostate cancer, breast cancer or any other malignancy, except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
- Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)
- Chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), ankylosing spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to be the principal cause of anemia
- Known hemosiderosis, hemochromatosis or hypercoagulable condition
- Any prior organ transplant or a scheduled organ transplantation date
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
- Kyntra Biocollaborator
Study Sites (359)
Research Site
Birmingham, Alabama, 35209, United States
Research Site
Huntsville, Alabama, 35805, United States
Research Site
Phoenix, Arizona, 85027, United States
Research Site
Bakersfield, California, 93309, United States
Research Site
El Centro, California, 92243, United States
Research Site
Escondido, California, 92025, United States
Research Site
Glendale, California, 91204, United States
Research Site
Long Beach, California, 90806, United States
Research Site
Long Beach, California, 90807, United States
Research Site
Los Angeles, California, 90022, United States
Research Site
Los Angeles, California, 90095, United States
Research Site
Lynwood, California, 90262, United States
Research Site
National City, California, 91950, United States
Research Site
Northridge, California, 91324, United States
Research Site
Orange, California, 92868, United States
Research Site
Sacramento, California, 95825, United States
Research Site
Sacramento, California, 95831, United States
Research Site
San Diego, California, 92103, United States
Research Site
San Dimas, California, 91773, United States
Research Site
San Francisco, California, 94110, United States
Research Site
San Luis Obispo, California, 93401, United States
Research Site
Upland, California, 91786, United States
Research Site
Arvada, Colorado, 80002, United States
Research Site
Waterbury, Connecticut, 06708, United States
Research Site
Aventura, Florida, 33180, United States
Research Site
Coral Gables, Florida, 33134, United States
Research Site
Coral Springs, Florida, 33071, United States
Research Site
Edgewater, Florida, 32132, United States
Research Site
Hollywood, Florida, 33021, United States
Research Site
Kissimmee, Florida, 34741, United States
Research Site
Lauderdale Lakes, Florida, 33313, United States
Research Site
Miami, Florida, 33126, United States
Research Site
Miami, Florida, 33130, United States
Research Site
Miami, Florida, 33133, United States
Research Site
Miami, Florida, 33145, United States
Research Site
Miami, Florida, 33150, United States
Research Site
Miami, Florida, 33165, United States
Research Site
Miami, Florida, 33169, United States
Research Site
Miami, Florida, 33173, United States
Research Site
Port Charlotte, Florida, 33952, United States
Research Site
Tampa, Florida, 33607, United States
Research Site
Atlanta, Georgia, 30342, United States
Research Site
Columbus, Georgia, 31901, United States
Research Site
Columbus, Georgia, 31904, United States
Research Site
Joliet, Illinois, 60435, United States
Research Site
La Grange, Illinois, 60525, United States
Research Site
Metairie, Louisiana, 70006, United States
Research Site
Shreveport, Louisiana, 71101, United States
Research Site
Rockport, Maine, 04856, United States
Research Site
Greenbelt, Maryland, 20770, United States
Research Site
Rockville, Maryland, 20852, United States
Research Site
Port Huron, Michigan, 48060, United States
Research Site
Gulfport, Mississippi, 39501, United States
Research Site
Kansas City, Missouri, 64111, United States
Research Site
Omaha, Nebraska, 68124, United States
Research Site
Las Vegas, Nevada, 89106, United States
Research Site
Las Vegas, Nevada, 89128, United States
Research Site
Reno, Nevada, 89511, United States
Research Site
Rochester, New Hampshire, 03867, United States
Research Site
Flushing, New York, 11355, United States
Research Site
Great Neck, New York, 11021, United States
Research Site
Charlotte, North Carolina, 28207, United States
Research Site
High Point, North Carolina, 27262, United States
Research Site
Jacksonville, North Carolina, 28546, United States
Research Site
New Bern, North Carolina, 28562, United States
Research Site
Wilmington, North Carolina, 28401, United States
Research Site
Cincinnati, Ohio, 45206, United States
Research Site
Cincinnati, Ohio, 45220, United States
Research Site
Columbus, Ohio, 43215, United States
Research Site
Oklahoma City, Oklahoma, 73116, United States
Research Site
Bethlehem, Pennsylvania, 18017, United States
Research Site
Lansdale, Pennsylvania, 19446, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Uniontown, Pennsylvania, 15401, United States
Research Site
Providence, Rhode Island, 02908, United States
Research Site
Providence, Rhode Island, 02915, United States
Research Site
Columbia, South Carolina, 29203, United States
Research Site
Knoxville, Tennessee, 37923, United States
Research Site
Corpus Christi, Texas, 78404, United States
Research Site
Cypress, Texas, 77429, United States
Research Site
Dallas, Texas, 75231, United States
Research Site
Houston, Texas, 77004, United States
Research Site
Houston, Texas, 77024, United States
Research Site
Houston, Texas, 77074, United States
Research Site
Houston, Texas, 77084, United States
Research Site
Houston, Texas, 77090, United States
Research Site
Houston, Texas, 77099, United States
Research Site
Lufkin, Texas, 75904, United States
Research Site
San Antonio, Texas, 78207, United States
Research Site
San Antonio, Texas, 78212, United States
Research Site
San Antonio, Texas, 78229, United States
Research Site
San Antonio, Texas, 78258, United States
Research Site
Salt Lake City, Utah, 84115, United States
Research Site
St. George, Utah, 84790, United States
Research Site
Norfolk, Virginia, 23507, United States
Research Site
Salem, Virginia, 24153, United States
Research Site
Woodbridge, Virginia, 22191, United States
Research Site
CABA, C1012AAR, Argentina
Research Site
CABA, C1440AAD, Argentina
Research Site
Capital Federal, C1425AGC, Argentina
Research Site
Ciudad Autónoma de Bs. As., C1199ABB, Argentina
Research Site
Ciudadela, 1702, Argentina
Research Site
La Plata, 1900, Argentina
Research Site
La Plata, C1427ARO, Argentina
Research Site
Lanús, B1824KAJ, Argentina
Research Site
Mar del Plata, 7600, Argentina
Research Site
Munro, 1605, Argentina
Research Site
Ramos Mejía, B1704ETD, Argentina
Research Site
Rosario, 2000, Argentina
Research Site
Rosario, S2000DNM, Argentina
Research Site
San Isidro, B1642DCD, Argentina
Research Site
San Miguel de Tucumán, 4000, Argentina
Research Site
Santa Rosa, 6300, Argentina
Research Site
Curitiba, 80230-130, Brazil
Research Site
Curitiba, 80440-020, Brazil
Research Site
Curitiba, 80810-040, Brazil
Research Site
Feira de Santana, 44001-584, Brazil
Research Site
Fortaleza, 60115282, Brazil
Research Site
Fortaleza, 60430-350, Brazil
Research Site
Fortaleza, 60430-370, Brazil
Research Site
Goiânia, 74043-011, Brazil
Research Site
Joinville, Brazil
Research Site
Juiz de Fora, 36036-330, Brazil
Research Site
Maringá, 87083-240, Brazil
Research Site
Porto Alegre, 90035-003, Brazil
Research Site
Porto Alegre, 90160-093, Brazil
Research Site
Porto Alegre, 90610-000, Brazil
Research Site
São Bernardo do Campo, 09715090, Brazil
Research Site
São Paulo, 01323-030, Brazil
Research Site
São Paulo, 04039-000, Brazil
Research Site
São Paulo, 05403-000, Brazil
Research Site
São Paulo, 08270-070, Brazil
Research Site
Botevgrad, 2140, Bulgaria
Research Site
Dupnitsa, 2600, Bulgaria
Research Site
Gotse Delchev, 2900, Bulgaria
Research Site
Haskovo, 6300, Bulgaria
Research Site
Kozloduy, 3320, Bulgaria
Research Site
Samokov, 2000, Bulgaria
Research Site
Sandanski, 2800, Bulgaria
Research Site
Silistra, 7500, Bulgaria
Research Site
Sliven, 8800, Bulgaria
Research Site
Smolyan, 3700, Bulgaria
Research Site
Yambol, 8600, Bulgaria
Research Site
Edmonton, Alberta, T6G 2B7, Canada
Research Site
Kamloops, British Columbia, V2C 2T1, Canada
Research Site
New Westminster, British Columbia, V3L 0A6, Canada
Research Site
Winnipeg, Manitoba, R2V 3M3, Canada
Research Site
Saint John, New Brunswick, E2L 4L2, Canada
Research Site
Sydney, Nova Scotia, B1P 1P3, Canada
Research Site
Brampton, Ontario, L6R 3J7, Canada
Research Site
Brampton, Ontario, L6T 0G1, Canada
Research Site
Kitchener, Ontario, N2H 5Z8, Canada
Research Site
London, Ontario, N6A 5A5, Canada
Research Site
Oakville, Ontario, L6K 3V3, Canada
Research Site
Scarborough Village, Ontario, M1H 3G4, Canada
Research Site
Toronto, Ontario, M4C 5T2, Canada
Research Site
Toronto, Ontario, M4S 1Y2, Canada
Research Site
Toronto, Ontario, M5C 2T2, Canada
Research Site
Toronto, Ontario, M9N 1N8, Canada
Research Site
Whitby, Ontario, L1N 5T2, Canada
Research Site
Gatineau, Quebec, J8Y 6S8, Canada
Research Site
Greenfield Park, Quebec, J4V 2H1, Canada
Research Site
Montreal, Quebec, H1T 2M4, Canada
Research Site
Montreal, Quebec, H4J 1C5, Canada
Research Site
Québec, Quebec, G1R 2J6, Canada
Research Site
Cali, 760032, Colombia
Research Site
Chía, 250008, Colombia
Research Site
Medellín, 5001000, Colombia
Research Site
Zipaquirá, 250258, Colombia
Research Site
Brno, 625 00, Czechia
Research Site
Havlíčkův Brod, 580 22, Czechia
Research Site
Ivančice, 664 91, Czechia
Research Site
Prague, 190 61, Czechia
Research Site
Rychnov nad Kněžnou, 516 01, Czechia
Research Site
Slaný, 274 01, Czechia
Research Site
Slavkov u Brna, Czechia
Research Site
Šumperk, 787 01, Czechia
Research Site
Ústí nad Labem, 401 13, Czechia
Research Site
Ústí nad Orlicí, 562 18, Czechia
Research Site
Berlin, 10117, Germany
Research Site
Cloppenburg, 49661, Germany
Research Site
Cologne, 50937, Germany
Research Site
Ajka, 8400, Hungary
Research Site
Budapest, 1096, Hungary
Research Site
Budapest, 1134, Hungary
Research Site
Gyula, 5700, Hungary
Research Site
Hatvan, 3000, Hungary
Research Site
Kecskemét, 6000, Hungary
Research Site
Nyíregyháza, 4400, Hungary
Research Site
Pécs, 7623, Hungary
Research Site
Polgár, 4090, Hungary
Research Site
Salgótarján, 3100, Hungary
Research Site
Siófok, 8600, Hungary
Research Site
Tatabánya, 2800, Hungary
Research Site
Velence, 2481, Hungary
Research Site
Ahmedabad, 380016, India
Research Site
Bangalore, 560052, India
Research Site
Bangalore, 560068, India
Research Site
Bangalore, 560070, India
Research Site
Chennai, 600006, India
Research Site
Ghaziabad NCR, 201012, India
Research Site
Hyderabad, 500018, India
Research Site
Hyderabad, 500072, India
Research Site
Kolkata, 700027, India
Research Site
Lucknow, 226003, India
Research Site
Maharashtra, 411013, India
Research Site
Mumbai, 400008, India
Research Site
Mysore, 570004, India
Research Site
Nagpur, 420012, India
Research Site
Nagpur, 440003, India
Research Site
Nagpur, 440012, India
Research Site
New Delhi, 110017, India
Research Site
New Delhi, 110060, India
Research Site
Pune, 411001, India
Research Site
Vijayawada, 520 008, India
Research Site
Vijayawada, 522002, India
Research Site
Visakhapatnam, 530002, India
Research Site
George Town, 10990, Malaysia
Research Site
Kubang Kerian, 16150, Malaysia
Research Site
Putrajaya, 62250, Malaysia
Research Site
Taiping, 34000, Malaysia
Research Site
Aguascalientes, 20219, Mexico
Research Site
Culiacán, 80230, Mexico
Research Site
Guadalajara, 44670, Mexico
Research Site
Guadalajara, 44676, Mexico
Research Site
México, 06726, Mexico
Research Site
Minatitlán, 96730, Mexico
Research Site
Veracruz, 91900, Mexico
Research Site
Xalapa, 91020, Mexico
Research Site
Bellavista, CALLAO 2, Peru
Research Site
Ica, Peru
Research Site
Lima, 14, Peru
Research Site
Lima, L17, Peru
Research Site
Lima, LIMA 01, Peru
Research Site
Lima, LIMA 1, Peru
Research Site
Lima, LIMA 27, Peru
Research Site
Lima, LIMA 31, Peru
Research Site
Trujillo, 044, Peru
Research Site
Cebu City, 6000, Philippines
Research Site
Iloilo City, 5000, Philippines
Research Site
Quezon City, 1101, Philippines
Research Site
Ciechanów, 06-400, Poland
Research Site
Gmina Końskie, 26-200, Poland
Research Site
Lodz, 90-141, Poland
Research Site
Poznan, 60-355, Poland
Research Site
Sochaczew, 96-500, Poland
Research Site
Tczew, 83-110, Poland
Research Site
Cidra, 00739, Puerto Rico
Research Site
Rio Piedras, 00935, Puerto Rico
Research Site
Río Grande, 00745, Puerto Rico
Research Site
San Juan, 00909, Puerto Rico
Research Site
San Juan, 00917, Puerto Rico
Research Site
San Juan, 00921, Puerto Rico
Research Site
San Juan, 00927, Puerto Rico
Research Site
Toa Baja, 00949, Puerto Rico
Research Site
Arad, 310017, Romania
Research Site
Bucharest, 010731, Romania
Research Site
Bucharest, 020475, Romania
Research Site
Târgu Mureş, 540000, Romania
Research Site
Timișoara, 300736, Romania
Research Site
Arkhangelsk, 163001, Russia
Research Site
Barnaul, 656024, Russia
Research Site
Irkutsk, 664049, Russia
Research Site
Izhevsk, 426035, Russia
Research Site
Kemerovo, 650066, Russia
Research Site
Krasnoyarsk, 660062, Russia
Research Site
Moscow, 105229, Russia
Research Site
Moscow, 109263, Russia
Research Site
Moscow, 129344, Russia
Research Site
Nizhny Novgorod, 603076, Russia
Research Site
Nizhny Novgorod, 603126, Russia
Research Site
Perm, 614000, Russia
Research Site
Ryazan, 390027, Russia
Research Site
Saint Petersburg, 191015, Russia
Research Site
Saint Petersburg, 194354, Russia
Research Site
Saint Petersburg, 196601, Russia
Research Site
Ufa, 450000, Russia
Research Site
Ufa, 450005, Russia
Research Site
Ufa, 450071, Russia
Research Site
Volgograd, 404120, Russia
Research Site
Bratislava, 82606, Slovakia
Research Site
Bratislava, 831 03, Slovakia
Research Site
Košice, 04011, Slovakia
Research Site
Kráľovský Chlmec, 077 01, Slovakia
Research Site
Nové Zámky, 940 34, Slovakia
Research Site
Zvolen, 960 01, Slovakia
Research Site
Ansan-si, 15355, South Korea
Research Site
Busan, 49241, South Korea
Research Site
Daegu, 42415, South Korea
Research Site
Daejeon, 35015, South Korea
Research Site
Goyang-si, 10380, South Korea
Research Site
Goyang-si, 10444, South Korea
Research Site
Incheon, 403-720, South Korea
Research Site
Seongnam-si, 13620, South Korea
Research Site
Seoul, 03312, South Korea
Research Site
Seoul, 06273, South Korea
Research Site
Seoul, 08308, South Korea
Research Site
Seoul, 139-711, South Korea
Research Site
Uijeongbu-si, 11765, South Korea
Research Site
Almería, 04009, Spain
Research Site
Málaga, 29010, Spain
Research Site
Santiago de Compostela, 15706, Spain
Research Site
Seville, 41013, Spain
Research Site
Valencia, 46010, Spain
Research Site
Valencia, 46017, Spain
Research Site
Valencia, 46026, Spain
Research Site
Kaohsiung City, 82445, Taiwan
Research Site
Keelung, 20401, Taiwan
Research Site
New Taipei City, 220, Taiwan
Research Site
New Taipei City, 231, Taiwan
Research Site
New Taipei City, 23561, Taiwan
Research Site
Taichung, 402, Taiwan
Research Site
Taipei, 0116, Taiwan
Research Site
Taipei, 10491, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan District, 333, Taiwan
Research Site
Bangkok, 10300, Thailand
Research Site
Bangkok, 10330, Thailand
Research Site
Bangkok, 10400, Thailand
Research Site
Bangkok, 10700, Thailand
Research Site
Khon Kaen, 40000, Thailand
Research Site
Khon Kaen, 40002, Thailand
Research Site
Adana, 01330, Turkey (Türkiye)
Research Site
Ankara, 06230, Turkey (Türkiye)
Research Site
Ankara, 06490, Turkey (Türkiye)
Research Site
Antalya, Turkey (Türkiye)
Research Site
Istanbul, 34093, Turkey (Türkiye)
Research Site
Istanbul, 34098, Turkey (Türkiye)
Research Site
Izmir, 35040, Turkey (Türkiye)
Research Site
Chernivtsi, 58002, Ukraine
Research Site
Dnipro, 49005, Ukraine
Research Site
Ivano-Frankivsk, 76008, Ukraine
Research Site
Kharkiv, 61002, Ukraine
Research Site
Kharkiv, 61039, Ukraine
Research Site
Kharkiv, 61058, Ukraine
Research Site
Kharkiv, 61103, Ukraine
Research Site
Khmelnytsky, 29000, Ukraine
Research Site
Kirovograd, 25006, Ukraine
Research Site
Kyiv, 01601, Ukraine
Research Site
Kyiv, 02125, Ukraine
Research Site
Kyiv, 04050, Ukraine
Research Site
Kyiv, 04107, Ukraine
Research Site
Kyiv, 04114, Ukraine
Research Site
Lutsk, 43005, Ukraine
Research Site
Lviv, 79010, Ukraine
Research Site
Odesa, 65009, Ukraine
Research Site
Rivne, 33027, Ukraine
Research Site
Vinnytsia, 21018, Ukraine
Research Site
Vinnytsia, 21029, Ukraine
Research Site
Zaporizhzhya, 69001, Ukraine
Research Site
Zaporizhzhya, 69068, Ukraine
Research Site
Zaporizhzhya, 69118, Ukraine
Research Site
Zaporizhzhya, 69600, Ukraine
Research Site
Can Tho, 900000, Vietnam
Research Site
Hanoi, 100000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Hochiminh, 550000, Vietnam
Research Site
Hochiminh, 700000, Vietnam
Research Site
Huế, 530000, Vietnam
Related Publications (3)
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
PMID: 36005278DERIVEDProvenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Little DJ, Houser MT, Frison L, Houghton J, Neff TB. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol. 2021 Aug;16(8):1190-1200. doi: 10.2215/CJN.16191020.
PMID: 34362786DERIVEDFishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol. 2021 Mar;32(3):737-755. doi: 10.1681/ASN.2020081150. Epub 2021 Feb 10.
PMID: 33568383DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Limitations and Caveats
20 participants were excluded from the analysis due to Good Clinical Practice violations or system technical issues (9 in roxadustat group and 11 in placebo group). Higher IP discontinuation was observed in placebo group versus in roxadustat group.
Results Point of Contact
- Title
- Global Clinical Lead
- Organization
- AstraZeneca
Study Officials
- PRINCIPAL INVESTIGATOR
Steven Fishbane, MD
Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA
- STUDY DIRECTOR
Mark Houser, MD
AZ R&D Gaithersburg, USA
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2014
First Posted
June 25, 2014
Study Start
June 26, 2014
Primary Completion
October 4, 2018
Study Completion
October 4, 2018
Last Updated
December 16, 2019
Results First Posted
December 16, 2019
Record last verified: 2019-11